Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Antidiabetics industry 360° synopsis, 2015 – 2026
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Patient population trends
2.1.4. Route of administration trends
2.1.5. Regional trends
Chapter 3. Antidiabetics Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2015 – 2026
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Strong product pipeline of antidiabetics
3.3.1.2. Globally rising prevalence of diabetes
3.3.1.3. Increasing prevalence of lifestyle induced disorders such as obesity
3.3.1.4. Growing adoption of oral antidiabetic drugs
3.3.1.5. Rising spending on R&D for innovative drugs
3.3.2. Industry pitfalls and challenges
3.3.2.1. Prohibitive cost of insulin
3.3.2.2. Safety issues pertaining to some diabetic drugs
3.4. Regulatory landscape
3.4.1. U.S.
3.4.2. Europe
3.5. Clinical workflow analysis
3.6. Reimbursement scenario
3.6.1. U.S.
3.6.2. Europe
3.6.3. Australia
3.7. Growth potential analysis
3.7.1. By product
3.7.2. By patient population
3.7.3. By route of administration
3.8. COVID-19 impact analysis
3.9. Porter’s analysis
3.10. Competitive landscape, 2019
3.11. PESTEL analysis
Chapter 4. Antidiabetics Market, By Product
4.1. Key segment trends
4.2. Insulin
4.2.1. Market size, by region, 2015 - 2026 (USD Million)
4.2.2. Rapid acting analog
4.2.2.1. Market size, by region, 2015-2026 (USD Million)
4.2.3. Long acting analog
4.2.3.1. Market size, by region, 2015-2026 (USD Million)
4.2.4. Premixed insulin
4.2.4.1. Market size, by region, 2015-2026 (USD Million)
4.2.5. Short acting analog
4.2.5.1. Market size, by region, 2015-2026 (USD Million)
4.2.6. Intermediate acting analog
4.2.6.1. Market size, by region, 2015-2026 (USD Million)
4.3. Drug class
4.3.1. Market size, by region, 2015 - 2026 (USD Million)
4.3.2. Alpha glucosidase inhibitors
4.3.2.1. Market size, by region, 2015-2026 (USD Million)
4.3.3. Biguanides
4.3.3.1. Market size, by region, 2015-2026 (USD Million)
4.3.4. Sulphonylureas
4.3.4.1. Market size, by region, 2015-2026 (USD Million)
4.3.5. GLP-1 (Glucagon like peptide) agonists
4.3.5.1. Market size, by region, 2015-2026 (USD Million)
4.3.6. DPP-IV (Dipeptidyl Peptidase) inhibitors
4.3.6.1. Market size, by region, 2015-2026 (USD Million)
4.3.7. Meglitinides
4.3.7.1. Market size, by region, 2015-2026 (USD Million)
4.3.8. SGLT-II (Sodium Glucose Transport Proteins) inhibitors
4.3.8.1. Market size, by region, 2015-2026 (USD Million)
4.3.9. Thiazolidinedione
4.3.9.1. Market size, by region, 2015-2026 (USD Million)
Chapter 5. Antidiabetics Market, By Patient Population
5.1. Key segment trends
5.2. Pediatric
5.2.1. Market size, by region, 2015 - 2026 (USD Million)
5.3. Adult
5.3.1. Market size, by region, 2015 - 2026 (USD Million)
5.4. Geriatric
5.4.1. Market size, by region, 2015 - 2026 (USD Million)
Chapter 6. Antidiabetics Market, By Route of Administration
6.1. Key segment trends
6.2. Insulin syringe/ Insulin pen
6.2.1. Market size, by region, 2015 - 2026 (USD Million)
6.3. Insulin pump
6.3.1. Market size, by region, 2015 - 2026 (USD Million)
6.4. Intravenous infusion
6.4.1. Market size, by region, 2015 - 2026 (USD Million)
6.5. Oral
6.5.1. Market size, by region, 2015 - 2026 (USD Million)
6.6. Others
6.6.1. Market size, by region, 2015 - 2026 (USD Million)
Chapter 7. Antidiabetics Market, By Region
7.1. Key regional trends
7.2. North America
7.2.1. Market size by country, 2015 – 2026 (USD Million)
7.2.2. Market size by product, 2015 – 2026 (USD Million)
7.2.2.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.2.2.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.2.3. Market size by patient population, 2015 – 2026 (USD Million)
7.2.4. Market size by route of administration, 2015 – 2026 (USD Million)
7.2.5. U.S.
7.2.5.1. Market size by product, 2015 - 2026 (USD Million)
7.2.5.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.2.5.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.2.5.2. Market size by patient population, 2015 – 2026 (USD Million)
7.2.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.2.6. Canada
7.2.6.1. Market size by product, 2015 - 2026 (USD Million)
7.2.6.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.2.6.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.2.6.2. Market size by patient population, 2015 – 2026 (USD Million)
7.2.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.3. Europe
7.3.1. Market size by country, 2015 – 2026 (USD Million)
7.3.2. Market size by product, 2015 – 2026 (USD Million)
7.3.2.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.3.2.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.3.3. Market size by patient population, 2015 – 2026 (USD Million)
7.3.4. Market size by route of administration, 2015 – 2026 (USD Million)
7.3.5. Germany
7.3.5.1. Market size by product, 2015 - 2026 (USD Million)
7.3.5.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.3.5.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.3.5.2. Market size by patient population, 2015 – 2026 (USD Million)
7.3.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.3.6. UK
7.3.6.1. Market size by product, 2015 - 2026 (USD Million)
7.3.6.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.3.6.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.3.6.2. Market size by patient population, 2015 – 2026 (USD Million)
7.3.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.3.7. France
7.3.7.1. Market size by product, 2015 - 2026 (USD Million)
7.3.7.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.3.7.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.3.7.2. Market size by patient population, 2015 – 2026 (USD Million)
7.3.7.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.3.8. Italy
7.3.8.1. Market size by product, 2015 - 2026 (USD Million)
7.3.8.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.3.8.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.3.8.2. Market size by patient population, 2015 – 2026 (USD Million)
7.3.8.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.3.9. Spain
7.3.9.1. Market size by product, 2015 - 2026 (USD Million)
7.3.9.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.3.9.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.3.9.2. Market size by patient population, 2015 – 2026 (USD Million)
7.3.9.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.4. Asia Pacific
7.4.1. Market size by country, 2015 – 2026 (USD Million)
7.4.2. Market size by product, 2015 – 2026 (USD Million)
7.4.2.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.4.2.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.4.3. Market size by patient population, 2015 – 2026 (USD Million)
7.4.4. Market size by route of administration, 2015 – 2026 (USD Million)
7.4.5. Japan
7.4.5.1. Market size by product, 2015 - 2026 (USD Million)
7.4.5.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.4.5.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.4.5.2. Market size by patient population, 2015 – 2026 (USD Million)
7.4.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.4.6. China
7.4.6.1. Market size by product, 2015 - 2026 (USD Million)
7.4.6.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.4.6.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.4.6.2. Market size by patient population, 2015 – 2026 (USD Million)
7.4.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.4.7. India
7.4.7.1. Market size by product, 2015 - 2026 (USD Million)
7.4.7.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.4.7.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.4.7.2. Market size by patient population, 2015 – 2026 (USD Million)
7.4.7.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.4.8. Australia
7.4.8.1. Market size by product, 2015 - 2026 (USD Million)
7.4.8.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.4.8.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.4.8.2. Market size by patient population, 2015 – 2026 (USD Million)
7.4.8.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.5. Latin America
7.5.1. Market size by country, 2015 – 2026 (USD Million)
7.5.2. Market size by product, 2015 – 2026 (USD Million)
7.5.2.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.5.2.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.5.3. Market size by patient population, 2015 – 2026 (USD Million)
7.5.4. Market size by route of administration, 2015 – 2026 (USD Million)
7.5.5. Brazil
7.5.5.1. Market size by product, 2015 - 2026 (USD Million)
7.5.5.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.5.5.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.5.5.2. Market size by patient population, 2015 – 2026 (USD Million)
7.5.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.5.6. Mexico
7.5.6.1. Market size by product, 2015 - 2026 (USD Million)
7.5.6.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.5.6.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.5.6.2. Market size by patient population, 2015 – 2026 (USD Million)
7.5.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.6. Middle East & Africa (MEA)
7.6.1. Market size by country, 2015 – 2026 (USD Million)
7.6.2. Market size by product, 2015 – 2026 (USD Million)
7.6.2.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.6.2.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.6.3. Market size by patient population, 2015 – 2026 (USD Million)
7.6.4. Market size by route of administration, 2015 – 2026 (USD Million)
7.6.5. South Africa
7.6.5.1. Market size by product, 2015 - 2026 (USD Million)
7.6.5.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.6.5.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.6.5.2. Market size by patient population, 2015 – 2026 (USD Million)
7.6.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
7.6.6. Saudi Arabia
7.6.6.1. Market size by product, 2015 - 2026 (USD Million)
7.6.6.1.1. Market size, by insulin, 2015 – 2026 (USD Million)
7.6.6.1.2. Market size, by drug class, 2015 – 2026 (USD Million)
7.6.6.2. Market size by patient population, 2015 – 2026 (USD Million)
7.6.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
Chapter 8. Company Profiles
8.1. Competitive dashboard, 2019
8.2. AstraZeneca
8.2.1. Business overview
8.2.2. Financial data
8.2.3. Product landscape
8.2.4. Strategic outlook
8.2.5. SWOT analysis
8.3. Bayer Corporation
8.3.1. Business overview
8.3.2. Financial data
8.3.3. Product landscape
8.3.4. Strategic outlook
8.3.5. SWOT analysis
8.4. Boehringer Ingelheim
8.4.1. Business overview
8.4.2. Financial data
8.4.3. Product landscape
8.4.4. Strategic outlook
8.4.5. SWOT analysis
8.5. Bristol-Myers Squibb
8.5.1. Business overview
8.5.2. Financial data
8.5.3. Product landscape
8.5.4. Strategic outlook
8.5.5. SWOT analysis
8.6. Eli Lilly
8.6.1. Business overview
8.6.2. Financial data
8.6.3. Product landscape
8.6.4. Strategic outlook
8.6.5. SWOT analysis
8.7. Halozyme Therapeutics
8.7.1. Business overview
8.7.2. Financial data
8.7.3. Product landscape
8.7.4. Strategic outlook
8.7.5. SWOT analysis
8.8. Johnson & Johnson
8.8.1. Business overview
8.8.2. Financial data
8.8.3. Product landscape
8.8.4. Strategic outlook
8.8.5. SWOT analysis
8.9. Merck & Co. Inc.
8.9.1. Business overview
8.9.2. Financial data
8.9.3. Product landscape
8.9.4. Strategic outlook
8.9.5. SWOT analysis
8.10. Novartis AG
8.10.1. Business overview
8.10.2. Financial data
8.10.3. Product landscape
8.10.4. Strategic outlook
8.10.5. SWOT analysis
8.11. Novo Nordisk
8.11.1. Business overview
8.11.2. Financial data
8.11.3. Product landscape
8.11.4. Strategic outlook
8.11.5. SWOT analysis
8.12. Oramed Pharmaceuticals Inc.
8.12.1. Business overview
8.12.2. Financial data
8.12.3. Product landscape
8.12.4. Strategic outlook
8.12.5. SWOT analysis
8.13. Pfizer
8.13.1. Business overview
8.13.2. Financial data
8.13.3. Product landscape
8.13.4. Strategic outlook
8.13.5. SWOT analysis
8.14. Sanofi
8.14.1. Business overview
8.14.2. Financial data
8.14.3. Product landscape
8.14.4. Strategic outlook
8.14.5. SWOT analysis
8.15. Takeda Pharmaceutical
8.15.1. Business overview
8.15.2. Financial data
8.15.3. Product landscape
8.15.4. Strategic outlook
8.15.5. SWOT analysis
